Advancing schizophrenia drug discovery: optimizing rodent models to bridge the translational gap

Area of Science:

• Neuroscience
• Psychiatry
• Pharmacology

Background:

• Despite advances in understanding schizophrenia pathophysiology, effective treatments remain elusive.
• Existing rodent models and behavioral endpoints have failed to translate into improved clinical therapies for schizophrenia.

Purpose of the Study:

• To critically evaluate current rodent models and behavioral endpoints in schizophrenia drug discovery.
• To propose novel, translational strategies for developing more effective schizophrenia therapeutics.

Main Methods:

• Critical assessment of existing rodent models and behavioral endpoints used in schizophrenia drug discovery.
• Review of recent advances in understanding schizophrenia genetics and neural circuitry.
• Perspective on developing integrated preclinical and clinical programs for rational drug discovery.

Main Results:

• Current models and endpoints have a significant translational gap, hindering drug discovery progress.
• New models incorporating genetic and neural circuit insights hold promise for bridging this gap.
• Rational drug discovery strategies are needed to replace serendipitous approaches.

Conclusions:

• Schizophrenia drug discovery requires a paradigm shift from inadequate models to rational, integrated strategies.
• Validation of drug targets in disease-based models with translationally relevant endpoints is crucial.
• Implementing these changes will reduce attrition rates and lead to therapies targeting the disease process.